Simon Harrison: Early Data on AMG 701 for Heavily Pretreated Relapsed/Refractory Multiple Myeloma

Simon Harrison, MBBS, PhD, shares results from a phase I first-in-human trial evaluating AMG 701, an anti‑BCMA BiTE® molecule, in patients with heavily pre‑treated relapsed/refractory multiple myeloma.